122 related articles for article (PubMed ID: 30569026)
1. Genetics of Glioblastoma in Moroccan population: Review of literature.
Idrissi HHE; Boujmia OKA; Nadifi S; Dehbi H
IBRO Rep; 2018 Dec; 5():133-136. PubMed ID: 30569026
[TBL] [Abstract][Full Text] [Related]
2.
Senhaji N; Louati S; Chbani L; El Fatemi H; Hammas N; Mikou K; Maaroufi M; Benzagmout M; Boujraf S; El Bardai S; Giry M; Marie Y; Chaoui El Faiz M; Mokhtari K; Idbaih A; Amarti A; Bennis S
Biomed Res Int; 2017; 2017():8045859. PubMed ID: 28785587
[TBL] [Abstract][Full Text] [Related]
3. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
Nobusawa S; Watanabe T; Kleihues P; Ohgaki H
Clin Cancer Res; 2009 Oct; 15(19):6002-7. PubMed ID: 19755387
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.
Watanabe K; Tachibana O; Sata K; Yonekawa Y; Kleihues P; Ohgaki H
Brain Pathol; 1996 Jul; 6(3):217-23; discussion 23-4. PubMed ID: 8864278
[TBL] [Abstract][Full Text] [Related]
5. p53 mutation and epidermal growth factor receptor overexpression in glioblastoma.
Yoon KS; Lee MC; Kang SS; Kim JH; Jung S; Kim YJ; Lee JH; Ahn KY; Lee JS; Cheon JY
J Korean Med Sci; 2001 Aug; 16(4):481-8. PubMed ID: 11511795
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway.
Das A; Tan WL; Teo J; Smith DR
J Neurooncol; 2002 Nov; 60(2):117-25. PubMed ID: 12635658
[TBL] [Abstract][Full Text] [Related]
7. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas.
Tohma Y; Gratas C; Van Meir EG; Desbaillets I; Tenan M; Tachibana O; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Mar; 57(3):239-45. PubMed ID: 9600216
[TBL] [Abstract][Full Text] [Related]
8. The definition of primary and secondary glioblastoma.
Ohgaki H; Kleihues P
Clin Cancer Res; 2013 Feb; 19(4):764-72. PubMed ID: 23209033
[TBL] [Abstract][Full Text] [Related]
9. p53 mutations versus EGF receptor expression in giant cell glioblastomas.
Peraud A; Watanabe K; Plate KH; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1997 Nov; 56(11):1236-41. PubMed ID: 9370234
[TBL] [Abstract][Full Text] [Related]
10. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
11. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas.
Sure U; Rüedi D; Tachibana O; Yonekawa Y; Ohgaki H; Kleihues P; Hegi ME
J Neuropathol Exp Neurol; 1997 Jul; 56(7):782-9. PubMed ID: 9210874
[TBL] [Abstract][Full Text] [Related]
12. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
[TBL] [Abstract][Full Text] [Related]
13. IDH1 mutation of gliomas with long-term survival analysis.
Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH
Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutations in primary and secondary glioblastomas.
Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
[TBL] [Abstract][Full Text] [Related]
15. Genetic profile of the giant cell glioblastoma.
Peraud A; Watanabe K; Schwechheimer K; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1999 Feb; 79(2):123-9. PubMed ID: 10068201
[TBL] [Abstract][Full Text] [Related]
16. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.
Aghi M; Gaviani P; Henson JW; Batchelor TT; Louis DN; Barker FG
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8600-5. PubMed ID: 16361543
[TBL] [Abstract][Full Text] [Related]
18. Genetic pathways to glioblastoma: a population-based study.
Ohgaki H; Dessen P; Jourde B; Horstmann S; Nishikawa T; Di Patre PL; Burkhard C; Schüler D; Probst-Hensch NM; Maiorka PC; Baeza N; Pisani P; Yonekawa Y; Yasargil MG; Lütolf UM; Kleihues P
Cancer Res; 2004 Oct; 64(19):6892-9. PubMed ID: 15466178
[TBL] [Abstract][Full Text] [Related]
19. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
Tohma Y; Gratas C; Biernat W; Peraud A; Fukuda M; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Jul; 57(7):684-9. PubMed ID: 9690672
[TBL] [Abstract][Full Text] [Related]
20. Concurrent EGFR amplification and TP-53 mutation in glioblastomas.
Gil-Benso R; Lopez-Gines C; Benito R; López-Guerrero JA; Callaghan RC; Pellín A; Roldán P; Cerdá-Nicolas M
Clin Neuropathol; 2007; 26(5):224-31. PubMed ID: 17907599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]